CureVac N.V. (CVAC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for CVAC in the last 30 days. The most recent was published Jan 16, 2026.
Latest news
25 items- SECSEC Form 15-12G filed by CureVac N.V.15-12G - CureVac N.V. (0001809122) (Filer)
- SECSEC Form S-8 POS filed by CureVac N.V.S-8 POS - CureVac N.V. (0001809122) (Filer)
- SECSEC Form 25-NSE filed by CureVac N.V.25-NSE - CureVac N.V. (0001809122) (Subject)
- SECSEC Form 6-K filed by CureVac N.V.6-K - CureVac N.V. (0001809122) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by CureVac N.V.SC TO-T/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by CureVac N.V.SC 14D9/A - CureVac N.V. (0001809122) (Subject)
- PRBioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA FieldBioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganizationCureVac will continue to operate under its existing organizational processes, while BioNTech will conclude the strategic, operational, and scientific analyses required to define the future organizational and portfolio setup MAINZ, Germany, December 18, 2025 – BioNTech SE
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CureVac N.V.SCHEDULE 13D/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CureVac N.V.SCHEDULE 13D/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CureVac N.V.SCHEDULE 13D/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by CureVac N.V.SC 14D9/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by CureVac N.V.SC TO-T/A - CureVac N.V. (0001809122) (Subject)
- SECSEC Form 425 filed by CureVac N.V.425 - CureVac N.V. (0001809122) (Subject)
- PRBioNTech Achieves Minimum Condition in CureVac Exchange OfferThe minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025 MAINZ, Germany, December 3, 2025 – BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that 184,071,410 shares of CureVac N.V. (NASDAQ:CVAC, "CureVac")), representing approximately 81.74% of CureVac's issued and outstanding shares, were validly tendered and not properly withdrawn prior to the expiration of the initial offering period at 9:00
- SECAmendment: SEC Form SC TO-T/A filed by CureVac N.V.SC TO-T/A - CureVac N.V. (0001809122) (Subject)
- SECSEC Form 425 filed by CureVac N.V.425 - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by CureVac N.V.SC 14D9/A - CureVac N.V. (0001809122) (Subject)
- SECSEC Form 6-K filed by CureVac N.V.6-K - CureVac N.V. (0001809122) (Filer)
- PRBioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time ExpirationOffer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of 0.05363 of a BioNTech American Depositary Share ("ADS") for each CureVac share, determined based on the volume-weighted average price of BioNTech ADSs over the 10 trading days ending November 25, 2025.CureVac shareholders approved matters related to BioNTech's exchange offer at their extraordinary general meeting held on November 25, 2025. MAINZ, Germany, November 26, 2025 – BioNTech SE (NASDAQ:BNTX, "BioNTech")) today announced the approval of matters relating to the exchange off
- NEWSCureVac Announces Voting Results of Extraordinary General MeetingTÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (NASDAQ:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).CureVac's shareholders approved all proposals relating to BioNTech SE's public exchange offer for all outstanding shares in CureVac (Offer) at the EGM with an approval rate of over 99.16% of the votes cast.The Offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac's shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2
- SECAmendment: SEC Form SC 14D9/A filed by CureVac N.V.SC 14D9/A - CureVac N.V. (0001809122) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by CureVac N.V.SC 14D9/A - CureVac N.V. (0001809122) (Subject)
- SECSEC Form 6-K filed by CureVac N.V.6-K - CureVac N.V. (0001809122) (Filer)
- NEWSCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business UpdatesGerman Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this yearOffer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is scheduled to expire on December 3, 2025German litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines has been paused pending completion of BioNTech's public exchange offerReceived Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC squamous non-small cell lung cancer (sqNSCLC)CVGBM (glioblastoma) Phase 1 Part B remains on
- SECSEC Form 425 filed by CureVac N.V.425 - CureVac N.V. (0001809122) (Subject)
CVAC FAQ
8 questionsWhat does CureVac N.V. do?
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer...What is the latest news on CVAC?
Quantisnow has not tracked any new filings, ratings or press releases for CVAC in the last 30 days. The most recent wire item was published on January 16, 2026.Where does CVAC stock trade?
CureVac N.V. (CVAC) is listed on NASDAQ.What sector and industry is CVAC in?
CureVac N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CureVac N.V. go public?
CureVac N.V. (CVAC) completed its IPO in 2020.What are analysts saying about CVAC?
Across the last 8 analyst actions on CureVac N.V., there were 2 upgrades and 3 downgrades. The most recent action was from Jefferies: Hold with a $5.00 price target on 2025-06-13.What companies are similar to CVAC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CVAC side-by-side with any of them on Quantisnow.How can I track CVAC on Quantisnow?
Quantisnow aggregates CureVac N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVAC to receive live email and push alerts on every new disclosure.